Linda West Biography and Net Worth

Director of Galera Therapeutics


Ms. West has served as a member of our Board of Directors since March 2020. Ms. West served in multiple leadership roles of increasing responsibility for E. I. du Pont de Nemours and Company from 1981 until her retirement in December 2019. Ms. West most recently served as Vice President, Corporate Planning and Analyses, where she led the execution of transformational transactions from October 2009 until her retirement including major divestitures, spins, acquisitions, and the merger with The Dow Company followed by simultaneous spins into three independent companies. Throughout her career with DuPont, Ms. West had P&L accountabilities varying from late to early stage businesses including DuPont Imaging Technologies, DuPont Personal Protection, DuPont Microcircuit Materials, and DuPont Industrial Imaging. In addition, Ms. West was the Chief Financial Officer of multiple DuPont businesses and was the Vice President, General Auditor and Chief Ethics and Compliance Officer for five years during the initial implementation of the Sarbanes-Oxley Act of 2002. Ms. West holds a B.S. in Accounting with a minor in Business Administration from the University of Delaware.

What is Linda West's net worth?

The estimated net worth of Linda West is at least $8,300.00 as of June 15th, 2021. Ms. West owns 40,000 shares of Galera Therapeutics stock worth more than $8,300 as of April 25th. This net worth estimate does not reflect any other assets that Ms. West may own. Learn More about Linda West's net worth.

How do I contact Linda West?

The corporate mailing address for Ms. West and other Galera Therapeutics executives is 2 WEST LIBERTY BOULEVARD SUITE 100, MALVERN PA, 19355. Galera Therapeutics can also be reached via phone at 610-725-1500 and via email at [email protected]. Learn More on Linda West's contact information.

Has Linda West been buying or selling shares of Galera Therapeutics?

Linda West has not been actively trading shares of Galera Therapeutics over the course of the past ninety days. Most recently, on Friday, December 17th, Linda West bought 20,000 shares of Galera Therapeutics stock. The stock was acquired at an average cost of $2.74 per share, with a total value of $54,800.00. Learn More on Linda West's trading history.

Linda West Insider Trading History at Galera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2021Buy20,000$2.74$54,800.00View SEC Filing Icon  
6/15/2021Buy10,000$9.13$91,300.0040,000View SEC Filing Icon  
6/2/2021Buy10,000$8.65$86,500.0030,000View SEC Filing Icon  
See Full Table

Linda West Buying and Selling Activity at Galera Therapeutics

This chart shows Linda West's buying and selling at Galera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Galera Therapeutics Company Overview

Galera Therapeutics logo
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.21
Low: $0.18
High: $0.21

50 Day Range

MA: $0.20
Low: $0.14
High: $0.27

2 Week Range

Now: $0.21
Low: $0.09
High: $3.59

Volume

668,207 shs

Average Volume

2,346,598 shs

Market Capitalization

$11.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17